- ￥108 - 998
- TargetMol
- USA
- T0182
- 2025年07月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
RT
- 保质期：
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -204℃ for several months.
- 英文名：
Clopidogrel
- 库存：
详询
- 供应商：
详询
- CAS号：
113665-84-2
- 规格：
2mg/10mg/50mg/100mg/1ml/10mM
| 规格： | 2mg | 产品价格： | ￥108.0 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ￥248.0 |
| 规格： | 50mg | 产品价格： | ￥638.5 |
| 规格： | 100mg | 产品价格： | ￥998.0 |
| 规格： | 1ml/10mM | 产品价格： | ￥218.0 |
ID：T0182
PURITY：0.99
Formula：C16H18ClNO6S2
MolWt：307.8
Appearance：白色粉末
Solubility：G4Water： 50.78 mg/L
Bioactivity：Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.
Status：USP, INN, BAN
Pathways：Metabolism
Target：P2 Receptor antagonist
Receptor：P2Y purinoceptor 12
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验血管疾病离开这个世界达 400 万人左右，其中近乎一半左右的死亡，源于急性冠状动脉综合征（ACS，包含心梗及不稳定心绞痛）。国内治疗 ACS 的标准疗法是二磷酸腺苷（ADP）受体抑制剂联合阿司匹林的双抗疗法，其中氯吡格雷 + 阿司匹林在我国广泛使用。实际上在氯吡格雷投入临床使用没多久之后，医生就发现很多患者出现氯吡格雷抵抗，就是这个药对患者无效。实际上，作为前体药物，氯吡格雷本身是不起作用的，它需要体内关键的酶处理之后才能发挥作用。对于氯吡格雷来说，这个关键的基因是 CYP2C19 基因。如果这个基因
Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist
Novel adenosine diphosphate (ADP) P2Y12 antagonists such as prasugrel, ticagrelor, cangrelor, and elinogrel are in various phases of clinical development. These ADP P2Y12 antagonists have advantages over clopidogrel ranging from faster onset
DMET Microarray Technology for Pharmacogenomics-Based Personalized Medicine
. The power of the DMET Assay has previously been demonstrated with regard to several different drugs including warfarin and clopidogrel. In a research study using an earlier four-color version of the assay, it was demonstrated that warfarin dosing
技术资料暂无技术资料 索取技术资料
